Related Experiment Video
Updated: Jun 24, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Rosiglitazone in Canada: experience in clinical practice
Beata Patasi1, Deborah MacNair, Ryan J Marble
1Faculty of Medicine, University of Ottawa, CMM- Division of Clinical and Functional Anatomy, 451 Smyth Rd, office # 2162, Ottawa, ON, K1H 8M5, Canada. bpatasi@uottawa.ca
Expert Opinion on Drug Metabolism & Toxicology
|April 17, 2009
Summary
Rosiglitazone is a safe and effective oral medication for managing type 2 diabetes, particularly for patients on metformin and sulfonylurea. This study confirms its benefits in a typical family practice setting.
Area of Science:
- Endocrinology
- Pharmacology
- Public Health
Background:
- Type 2 diabetes mellitus (T2DM) presents a significant global health challenge.
- Family practitioners are the primary care providers for most T2DM patients in North America.
- Rosiglitazone, an oral hypoglycemic agent, was introduced in Canada in 2000.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of rosiglitazone.
- To assess rosiglitazone in a typical T2DM population within a family practice setting.
- To examine its use alongside various drug therapies and in patients with comorbidities.
Main Methods:
- Observational, prospective, cohort, open-label study design.
- Inclusion of patients receiving care in a family practice setting.
- Assessment of rosiglitazone in patients on metformin and sulfonylurea therapies.
Main Results:
- Rosiglitazone demonstrated safety and effectiveness over a seven-and-a-half-year period.
- The study focused on patients with T2DM receiving maximal tolerated or therapeutic doses of other medications.
- Clinical practice experience supports rosiglitazone's role in T2DM management.
Conclusions:
- Rosiglitazone is a safe and effective treatment option for type 2 diabetes.
- Its efficacy is confirmed in patients concurrently treated with metformin and sulfonylurea.
- The family practice setting is a suitable environment for assessing and utilizing rosiglitazone.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...